drugset / Trial / NCT06062563
Study of Anlotinib in Patients With Radioiodine Refractory Differentiated Thyroid Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study aims to observe and explore the efficacy and safety of Anlotinib combined with penpulimab in the treatment of radioiodine refractory differentiated thyroid cancer with first-line resistance to angiogenesis inhibitors, and to summarize the treatment experience of population.
Timeline
- Start
- 2023-11-11
- Primary completion
- 2024-12-20
- Completion
- 2025-08-20
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | — |
| Subject | Penpulimab | Monoclonal antibody | 200 mg | — |
Indications
No indication recorded.